COMPASS THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $850.0K | $0 | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $56.0M | $42.3M | $38.1M | — | — | $14.9M | $22.4M |
| SG&A Expense | — | $16.9M | $15.1M | $12.2M | $11.7M | $10.9M | $12.9M | $11.6M |
| Operating Income | — | $-72.8M | $-56.6M | $-50.4M | $-41.7M | $-81.9M | $-27.8M | $-34.1M |
| Operating Margin | — | — | -6,661.8% | — | — | — | — | — |
| Interest Expense | — | — | — | — | $0 | $370.0K | $908.0K | $1.2M |
| Pretax Income | — | — | — | $-42.5M | $-39.2M | $-82.2M | $-29.5M | $-34.7M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $32.0K | $91.0K |
| Net Income | — | $-66.5M | $-49.4M | $-42.5M | $-39.2M | $-82.2M | $-29.5M | $-34.7M |
| Net Margin | — | — | -5,808.8% | — | — | — | — | — |
| EPS (Basic) | — | $-0.42 | $-0.36 | $-0.33 | $-0.37 | $-1.31 | $-0.96 | $-5.19 |
| EPS (Diluted) | — | — | — | — | — | $-1.31 | $-0.96 | $-5.19 |
| Shares Outstanding (Basic) | 180.1M | 157.7M | 137.4M | 127.0M | 105.2M | 62.9M | 51.2M | 7.0M |
| Shares Outstanding (Diluted) | 180.1M | 157.7M | 137.4M | 127.0M | 105.2M | 62.9M | 51.2M | 7.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |